Enterococcal Membrane Vesicles as Vaccine Candidates.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Enterococcus faecium* ; Vancomycin-Resistant Enterococci* ; Vaccines* ; Gram-Positive Bacterial Infections*/prevention & control ; Gram-Positive Bacterial Infections*/drug therapy; Animals ; Humans ; Rabbits ; Enterococcus faecalis ; Anti-Bacterial Agents/therapeutic use ; Microbial Sensitivity Tests

Enterococcus faecium is a leading cause of nosocomial infections, particularly in immunocompromised patients. The rise of multidrug-resistant E. faecium , including Vancomycin-Resistant Enterococci (VRE), is a major concern. Vaccines are promising alternatives to antibiotics, but there is currently no vaccine available against enterococci. In a previous study, we identified six protein vaccine candidates associated with extracellular membrane vesicles (MVs) produced by nosocomial E. faecium . In this study, we immunized rabbits with two different VRE-derived MV preparations and characterized the resulting immune sera. Both anti-MV sera exhibited high immunoreactivity towards the homologous strain, three additional VRE strains, and eight different unrelated E. faecium strains representing different sequence types (STs). Additionally, we demonstrated that the two anti-MV sera were able to mediate opsonophagocytic killing of not only the homologous strain but also three unrelated heterologous VRE strains. Altogether, our results indicate that E. faecium MVs, regardless of the purification method for obtaining them, are promising vaccine candidates against multidrug-resistant E. faecium and suggest that these naturally occurring MVs can be used as a multi-antigen platform to elicit protective immune responses against enterococcal infections.

Infect Immun. 2009 Jan;77(1):472-84. (PMID: 19001078)
PLoS One. 2011 Mar 18;6(3):e17839. (PMID: 21437253)
J Infect Dis. 2019 Oct 8;220(10):1589-1598. (PMID: 31289829)
Vaccine. 2013 Oct 25;31(45):5262-8. (PMID: 24012570)
Infect Immun. 2021 Mar 17;89(4):. (PMID: 33318138)
J Proteomics. 2018 Sep 15;187:28-38. (PMID: 29857065)
Eur J Immunol. 2017 Oct;47(10):1584-1797. (PMID: 29023707)
Semin Immunol. 2020 Aug;50:101433. (PMID: 33309166)
Front Microbiol. 2015 Aug 11;6:823. (PMID: 26322032)
Cells. 2020 Nov 02;9(11):. (PMID: 33147722)
Infect Immun. 2003 Sep;71(9):5033-41. (PMID: 12933846)
Int J Mol Sci. 2021 Apr 08;22(8):. (PMID: 33917862)
Drug Resist Updat. 2020 Dec;53:100732. (PMID: 33189998)
PLoS One. 2015 Aug 31;10(8):e0136625. (PMID: 26322633)
PLoS One. 2023 May 8;18(5):e0285170. (PMID: 37155660)
Infect Immun. 1999 Mar;67(3):1213-9. (PMID: 10024563)
Nat Rev Microbiol. 2012 Mar 16;10(4):266-78. (PMID: 22421879)
ACS Infect Dis. 2020 Jul 10;6(7):1816-1826. (PMID: 32364376)
PLoS One. 2014 Nov 04;9(11):e111880. (PMID: 25369230)
Front Microbiol. 2018 Feb 20;9:262. (PMID: 29515544)
Sci Rep. 2022 Dec 24;12(1):22324. (PMID: 36566282)
Lancet. 1991 Nov 2;338(8775):1093-6. (PMID: 1682541)
Sci Transl Med. 2018 Aug 1;10(452):. (PMID: 30068573)
Front Immunol. 2021 Nov 08;12:752168. (PMID: 34819933)
Drug Resist Updat. 2018 Sep;40:25-39. (PMID: 30447411)
Clin Infect Dis. 2005 Aug 1;41(3):327-33. (PMID: 16007529)
Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1901-3. (PMID: 26194692)
PLoS One. 2016 Mar 01;11(3):e0149132. (PMID: 26930282)
Vaccine. 2011 Aug 5;29(34):5705-10. (PMID: 21679737)
PLoS One. 2015 Sep 02;10(9):e0136021. (PMID: 26333035)
J Immunol Res. 2017;2017:7931982. (PMID: 28210633)
Front Microbiol. 2022 Dec 21;13:1029146. (PMID: 36620013)
Antibiotics (Basel). 2022 Jun 26;11(7):. (PMID: 35884110)
Molecules. 2018 Jun 15;23(6):. (PMID: 29914046)
Genome Biol Evol. 2013;5(8):1524-35. (PMID: 23882129)
Infect Immun. 2019 Aug 21;87(9):. (PMID: 31285252)
Microbiology (Reading). 2011 Dec;157(Pt 12):3429-3434. (PMID: 21903755)
J Hosp Infect. 2019 Dec;103(4):435-440. (PMID: 31449920)
Microlife. 2021 Apr 12;2:uqab002. (PMID: 37223255)
J Bacteriol. 2010 May;192(9):2469-70. (PMID: 20207762)
Carbohydr Res. 1999 Mar 31;316(1-4):155-60. (PMID: 10420594)
Lancet. 2013 Mar 9;381(9869):825-35. (PMID: 23324563)
PLoS One. 2015 Feb 23;10(2):e0118405. (PMID: 25706415)
Nat Rev Immunol. 2015 Jun;15(6):375-87. (PMID: 25976515)
Biotechnol J. 2015 Sep;10(11):1689-706. (PMID: 26912077)

HNF1474-19 Northern Norway Regional Health Authority

Keywords: Enterococcus faecium; VRE; bacterial membrane vesicles; infection control; vaccine

0 (Anti-Bacterial Agents)
0 (Vaccines)

Date Created: 20231125 Date Completed: 20231127 Latest Revision: 20231127

20231128

PMC10671723

10.3390/ijms242216051

38003243